Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
A patient with inflammatory breast carcinoma (IBC) diagnosed in the left breast responded to cisplatin and was treated with radical mastectomy and adjuvant therapy. Two years later C-erbB2-positive IBC was diagnosed in the right breast, and was treated with mastectomy and radiotherapy. Two years later skin metastases appeared, and trastuzumab was started initially as monotherapy, and later with paclitaxel and capecitabine. More than 12 years after diagnosis and 7 years after trastuzumab was started, the patient remains in complete clinical remission on trastuzumab and capecitabine.
Lázaro
Alicia
A
Servicio de Farmacia Hospitalaria, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Casinello
Javier
J
Amorós
Almudena
A
Heredia
Miriam
M
López-Alfonso
Ana
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000069287:Capecitabine; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D002945:Cisplatin / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008408:Mastectomy; D016609:Neoplasms, Second Primary; D017239:Paclitaxel / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D015996:Survival Rate; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000069287:Capecitabine; D002945:Cisplatin; D003841:Deoxycytidine; D005472:Fluorouracil; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
Cochrane Database Syst Rev. 2004;(2):CD003374
15106201
Oncology (Williston Park). 2004 Dec;18(14 Suppl 12):32-6
15685824
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8
10716719
Clin Breast Cancer. 2001 Oct;2(3):190-208; discussion 209
11899413
Eur J Cancer. 1994;30A(7):921-7
7946584
J Clin Oncol. 2002 Feb 1;20(3):719-26
11821453
J Clin Oncol. 2007 Aug 1;25(22):3246-50
17577021
Breast Cancer Res. 2000;2(6):423-9
11250736
N Engl J Med. 2001 Mar 15;344(11):783-92
11248153
Cancer. 1998 Jun 15;82(12):2366-72
9635529
Breast Cancer Res Treat. 2003;79 Suppl 1:S11-8
12868801